Vitrolife AB (VITR) AI Stock Analysis

• Market Cap: kr19.19B
• Dividend Yield: 0.79%
• Average Volume (3M): 81.63K
• Price to Earnings (P/E): 42.2
• Beta (1Y): 0.78
• Revenue Growth: 0.14%
• EPS Growth: N/A
• Country: SE
• Employees: 1,150
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.74
• Shares Outstanding: 135,447,190
• 10 Day Avg. Volume: 81,839
• 30 Day Avg. Volume: 81,627
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: kr139.00
• Price Target Upside: 0.43% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 57 Neutral
• Price Target: kr139.00 ▲(0.43% Upside)

Vitrolife AB's overall stock score is driven by its strong financial stability and profitability, despite recent challenges in revenue and cash flow growth. The technical analysis indicates a bearish trend, and the high P/E ratio suggests potential overvaluation. The lack of earnings call data and corporate events means these factors do not influence the score.

Vitrolife AB Business Overview & Revenue Model

Company Description

Vitrolife AB (publ), a medical device company, develops, produces, and markets products for assisted reproduction. It provides oocyte retrieval needles; sperm processing; in vitro fertilization media and oil; micromanipulation pipettes; labware; incubators; cryopreservation; and preimplantation genetic testing products. The company also offers EmbryoScope and Primo Vision time-lapse systems; time-lapse dishes; evaluation tools for time-lapse systems; and Octax laser and imaging systems, as well as log and guard systems and wireless sensors. It operates in Europe, the Middle East, and Africa; Asia; Japan and Pacific; and North and South America. The company was formerly known as Scandinavian IVF Science and changed its name to Vitrolife AB (publ) in 1998. Vitrolife AB (publ) was founded in 1994 and is headquartered in Gothenburg, Sweden.

How the Company Makes Money

Vitrolife generates revenue through multiple key streams related to its core offerings in the fertility market. The primary revenue source comes from the sale of its specialized culture media and consumables, which are essential for embryo culture and preservation during IVF treatments. Additionally, the company earns income from laboratory equipment sales, including incubators and other high-tech devices used in ART clinics. A significant part of its revenue is also derived from partnerships with fertility clinics and hospitals, where they provide ongoing support, training, and maintenance for their products. Furthermore, Vitrolife invests in research and development to innovate and expand its product portfolio, which helps in maintaining a competitive edge and attracting new customers, ultimately contributing to its overall earnings.

Vitrolife AB Financial Statement Overview

Summary

Vitrolife AB shows strong profitability with healthy margins, but recent declines in revenue and free cash flow pose potential risks. The balance sheet is robust with low leverage and strong equity, providing financial stability. Overall, the company is financially stable but needs to address recent growth challenges.

Income Statement

Vitrolife AB's income statement shows a mixed performance. The TTM data indicates a slight decline in revenue growth rate at -1.94%, which is concerning. However, the company maintains a healthy gross profit margin of 58.83% and a net profit margin of 12.86%, reflecting stable profitability. The EBIT and EBITDA margins are also robust at 19.36% and 25.60% respectively, although they have decreased compared to the previous year. Overall, the company demonstrates strong profitability, but the recent revenue decline is a potential risk.

Balance Sheet

Vitrolife AB's balance sheet is solid with a low debt-to-equity ratio of 0.15, indicating conservative leverage. The return on equity (ROE) is modest at 3.42%, suggesting room for improvement in generating returns for shareholders. The equity ratio is strong, with stockholders' equity comprising a significant portion of total assets, indicating financial stability. Overall, the balance sheet reflects a stable financial position with low leverage and good equity strength.

Cash Flow

The cash flow statement reveals some challenges for Vitrolife AB. The free cash flow growth rate is negative at -6.63%, indicating a decline in cash generation. However, the operating cash flow to net income ratio is healthy at 1.08, suggesting efficient cash conversion from earnings. The free cash flow to net income ratio is also strong at 0.93, indicating good cash flow relative to profits. Despite the decline in free cash flow growth, the company maintains a solid cash flow position relative to its net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.54B	3.61B	3.51B	3.23B	1.68B	1.25B
Gross Profit	2.08B	2.14B	1.98B	1.78B	1.05B	767.67M
EBITDA	906.00M	783.00M	-3.19B	993.00M	579.60M	438.65M
Net Income	455.00M	513.00M	-3.85B	394.00M	341.00M	286.85M
Balance Sheet
Total Assets	16.86B	17.45B	16.33B	20.55B	19.43B	2.31B
Cash, Cash Equivalents and Short-Term Investments	921.00M	1.14B	861.00M	578.00M	630.09M	973.57M
Total Debt	1.99B	2.09B	2.09B	2.23B	2.48B	62.40M
Total Liabilities	3.57B	3.81B	3.61B	3.81B	4.09B	288.07M
Stockholders Equity	13.28B	13.64B	12.72B	16.74B	15.32B	2.01B
Cash Flow
Free Cash Flow	648.00M	907.00M	638.00M	549.00M	321.86M	336.36M
Operating Cash Flow	694.00M	907.00M	757.00M	636.00M	384.31M	356.45M
Investing Cash Flow	-291.00M	-377.00M	-124.00M	-144.00M	-6.52B	-20.22M
Financing Cash Flow	-281.00M	-286.00M	-300.00M	-582.00M	5.75B	-26.61M

Vitrolife AB Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 138.40
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:VITR, the sentiment is Positive. The current price of 138.4 is above the 20-day moving average (MA) of 133.21, above the 50-day MA of 135.49, and below the 200-day MA of 162.89, indicating a neutral trend. The MACD of 0.38 indicates Negative momentum. The RSI at 57.11 is Neutral, neither overbought nor oversold. The STOCH value of 85.23 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:VITR.

Vitrolife AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CEVI	71 Outperform	$4.39B	28.15	18.65%	1.37%	3.45%	4.22%
GETI.B	62 Neutral	kr58.12B	38.63	4.94%	2.16%	6.51%	-42.34%
SECT.B	59 Neutral	€59.55B	99.60	31.78%	0.36%	5.74%	30.96%
VITR	57 Neutral	kr19.19B	42.17	3.46%	0.79%	0.14%	―
XVIVO	57 Neutral	$5.52B	49.55	5.17%	―	17.78%	-7.83%
BICO	54 Neutral	$1.52B	―	-15.03%	―	-21.56%	70.41%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Vitrolife AB Corporate Events

Vitrolife AB Reports Q2 2025 Results Amid Currency Challenges

Vitrolife AB reported a flat growth in local currencies for the second quarter of 2025, with a notable impact from currency fluctuations leading to a 7% decrease in sales in SEK. The company saw a strong performance in its Consumables segment with a 9% growth, while Technologies and Genetics saw declines. Despite the challenging currency environment, Vitrolife acquired a leading stake in AutoIVF and secured a EUR 300 million loan to refinance existing debt and support corporate purposes, indicating strategic moves to strengthen its market position.